醒脑静注射液治疗急性脑梗死的临床观察

发布时间：2018-03-19 16:41

本文选题：醒脑静注射液　切入点：急性脑梗死　出处：《中国药房》2017年32期 　论文类型：期刊论文

【摘要】：目的:探讨醒脑静注射液对急性脑梗死患者的临床疗效及安全性,以及对患者神经功能、生活活动能力、炎症细胞因子和昏迷度评分的影响。方法:选取2015年6月-2016年1月重庆市人民医院收治的脑梗死患者90例。按照随机数字表法分为对照组和观察组,各45例。对照组患者进行常规治疗,给予硫酸氢氯吡格雷片75 mg,po,qd+尼莫地平片20 mg,po,tid;观察组患者在此基础上给予醒脑静注射液20 m L加至0.9%氯化钠注射液250 m L中,ivgtt,qd。两组患者均连续治疗14 d。观察两组患者临床疗效,治疗前后美国国立卫生研究院卒中量表(NIHSS)、Barthel指数和Glasow昏迷度评定量表评分以及肿瘤坏死因子α(TNF-α)和白细胞介素6(IL-6)水平,并记录不良反应发生情况。结果:观察组患者临床总有效率(91.11%)显著高于对照组(73.33%),差异有统计学意义(P0.05)。治疗前,两组患者NIHSS、Barthel指数和Glasow昏迷度评定量表评分以及TNF-α和IL-6水平比较,差异均无统计学意义(P0.05)。治疗后,两组患者NIHSS评分、TNF-α及IL-6水平显著降低,Barthel指数显著升高,且观察组患者上述指标改善程度均显著优于对照组,差异均有统计学意义(P0.05);治疗14 d后,对照组患者Glasow昏迷度评分显著高于治疗前;治疗1、5、14 d后,观察组患者Glasow昏迷度评分显著高于治疗前,且显著高于对照组,差异均有统计学意义(P0.05)。观察组患者的总不良反应发生率(6.67%)显著低于对照组(13.33%),差异有统计学意义(P0.05)。结论:醒脑静注射液治疗急性脑梗死患者的临床疗效显著,能有效改善患者的神经功能和生活活动能力,促进患者苏醒,降低炎症因子水平,且安全性较高。
[Abstract]:Objective: to investigate the clinical efficacy and safety of Xingnaojing injection in patients with acute cerebral infarction, as well as its neurologic function and living ability. Effects of inflammatory cytokines and coma score. Methods: 90 patients with cerebral infarction admitted to Chongqing people's Hospital from June 2015 to January 2016 were divided into control group and observation group according to random digital table method. There were 45 cases in each group. The patients in the control group were treated with routine therapy. The patients in the observation group were treated with Xingnaojing injection 20ml / L and 0.9% mL sodium chloride injection 250ml / L respectively. The patients in both groups were treated continuously for 14 days. Before and after treatment, the National Institutes of Health Stroke scale (NIH) Barthel Index, Glasow coma rating scale (Glasow), tumor necrosis factor alpha (TNF- 伪) and interleukin-6 (IL-6) were measured. Results: the total effective rate of the observation group was significantly higher than that of the control group (P 0.05). Before treatment, the scores of NIHSS Barthel index, Glasow coma rating scale, TNF- 伪 and IL-6 were compared between the two groups. After treatment, the levels of NIHSS score, TNF- 伪 and IL-6 in the two groups were significantly lower than those in the control group, and the improvement degree of the above indexes in the observation group was significantly better than that in the control group (P 0.05), and 14 days after treatment, the improvement degree of the above indexes in the observation group was significantly higher than that in the control group (P 0.05). The Glasow coma score of the control group was significantly higher than that of the control group, and the Glasow coma score of the observation group was significantly higher than that of the control group after 14 days of treatment, and was significantly higher than that of the control group. The incidence of total adverse reactions in the observation group was significantly lower than that in the control group (P 0.05), and the difference was statistically significant (P 0.05). Conclusion: the clinical efficacy of Xingnaojing injection in the treatment of patients with acute cerebral infarction is significant. It can effectively improve the nervous function and living ability of the patients, promote the patients to wake up, reduce the level of inflammatory factors, and the safety is higher.
【作者单位】：重庆市人民医院药剂科;重庆市江津区中心医院神内科;重庆市人民医院重症医学科;
【分类号】：R743.33

【相似文献】